Recent Research Analysts’ Ratings Changes for Agios Pharmaceuticals (AGIO)

Several brokerages have updated their recommendations and price targets on shares of Agios Pharmaceuticals (NASDAQ: AGIO) in the last few weeks:

  • 11/7/2018 – Agios Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 11/2/2018 – Agios Pharmaceuticals had its “buy” rating reaffirmed by analysts at Cowen Inc.
  • 11/1/2018 – Agios Pharmaceuticals was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.
  • 11/1/2018 – Agios Pharmaceuticals had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings Inc..
  • 10/13/2018 – Agios Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 10/6/2018 – Agios Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 9/27/2018 – Agios Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 9/24/2018 – Agios Pharmaceuticals is now covered by analysts at Leerink Swann. They set a “market perform” rating and a $80.00 price target on the stock.
  • 9/19/2018 – Agios Pharmaceuticals was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 9/17/2018 – Agios Pharmaceuticals is now covered by analysts at Guggenheim. They set a “neutral” rating on the stock.
  • 9/11/2018 – Agios Pharmaceuticals was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.

AGIO stock traded down $2.82 during trading on Friday, hitting $69.09. 364,868 shares of the stock traded hands, compared to its average volume of 460,709. Agios Pharmaceuticals Inc has a 1 year low of $51.62 and a 1 year high of $99.82. The company has a market capitalization of $4.15 billion, a price-to-earnings ratio of -10.24 and a beta of 2.04.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($1.63) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.62) by ($0.01). Agios Pharmaceuticals had a negative net margin of 461.78% and a negative return on equity of 48.51%. The firm had revenue of $15.20 million for the quarter, compared to analysts’ expectations of $22.72 million. During the same period last year, the company posted ($1.59) earnings per share. The business’s revenue for the quarter was up 33.8% compared to the same quarter last year. As a group, analysts anticipate that Agios Pharmaceuticals Inc will post -6.12 EPS for the current year.

In other news, insider Christopher Bowden sold 1,700 shares of the firm’s stock in a transaction dated Thursday, August 30th. The shares were sold at an average price of $80.03, for a total transaction of $136,051.00. Following the sale, the insider now owns 1,224 shares of the company’s stock, valued at approximately $97,956.72. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Scott Biller sold 3,000 shares of the firm’s stock in a transaction dated Monday, November 5th. The shares were sold at an average price of $69.69, for a total transaction of $209,070.00. Following the sale, the insider now directly owns 53,932 shares in the company, valued at approximately $3,758,521.08. The disclosure for this sale can be found here. Insiders have sold a total of 26,305 shares of company stock worth $1,943,413 over the last three months. 3.02% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the company. First Trust Advisors LP lifted its stake in shares of Agios Pharmaceuticals by 58.8% in the 3rd quarter. First Trust Advisors LP now owns 1,162,010 shares of the biopharmaceutical company’s stock worth $89,614,000 after purchasing an additional 430,216 shares during the period. Woodford Investment Management Ltd bought a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth approximately $32,849,000. Wells Fargo & Company MN lifted its stake in shares of Agios Pharmaceuticals by 459.8% in the 2nd quarter. Wells Fargo & Company MN now owns 407,393 shares of the biopharmaceutical company’s stock worth $34,315,000 after purchasing an additional 334,617 shares during the period. Castleark Management LLC bought a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth approximately $8,114,000. Finally, Dimensional Fund Advisors LP bought a new position in shares of Agios Pharmaceuticals in the 1st quarter worth approximately $6,268,000. 94.38% of the stock is currently owned by hedge funds and other institutional investors.

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Featured Story: Hedge Funds – Risk or Reward?

Receive News & Ratings for Agios Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply